Lonza Acquires InterHealth Nutraceuticals

August 18, 2016

The up to $300-million transaction broadens Lonza’s offerings in sports nutrition, weight management, and immune health, in addition to several new health areas.

Ingredients supplier Lonza (Basel, Switzerland) announced this week it will acquire InterHealth Nutraceuticals (Benicia, CA) for up to $300 million. The move brings InterHealth’s more than 15 branded ingredients into Lonza’s portfolio, including several additions that complement Lonza’s existing offerings in sports nutrition, immune health, pet health, and weight management. Lonza will also be entering some new health areas as a result of the acquisition, including cognitive health and diabetic health.

“With this acquisition Lonza is taking a further step along our strategic path as a high-value supplier to the healthcare continuum,” said Richard Ridinger, Lonza’s CEO. “Lonza will leverage the successful product portfolio of InterHealth on a global level and in turn will be able to benefit from InterHealth’s proven management and branding capabilities to promote Lonza’s existing product portfolio.”

The acquisition will include InterHealth’s “cornerstone ingredient,” UC-II collagen for joint function, Lonza notes. A recent study found UC-II may be more effective at improving symptoms of knee osteoarthritis than a placebo or glucosamine hydrochloride plus chondroitin sulfate.

The acquisition is expected to close in September.

 

Read more:

Protein Plays Big in Top 2015 Acquisitions and Investments

L-Carnitine for Active Millennials is “Untapped Business Opportunity,” Survey Suggests

UC-II Collagen More Effective for Knee Osteoarthritis Symptoms than Glucosamine and Chondroitin?

 

Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com